According to latest industry reports, the global Single-Use Bioprocessing Market is expected to expand significantly over the next decade, driven by increasing R&D activities, bio ...

The life science group Sartorius today released its Annual Report for 2024. The document is available at the following link: Financial ...

Morgan Stanley (NYSE:MS) upgraded Sartorius AG (ETR:SATG) (SRT3:GR) (OTC: SARTF), a prominent player in the bioprocessing industry, from Equalweight to Overweight, while also increasing the price ...

TD Cowen began coverage on Repligen Corporation (NASDAQ:RGEN), a prominent bioprocessing company, with a Buy rating and a price target set at $200. The firm highlighted Repligen's strong position for ...

EQS-News: SARTORIUS AG / Key word (s): Dividend The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share (news with additional features) 07.02.2025 / 15:48 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on ...

CapEx for R&D and Infrastructure: EUR340 million, with a CapEx ratio of 12.2%. Sartorius AG (SARTF) achieved its reverse guidance for 2024, with both top-line and profitability meeting expectations.